Moderna Inc. Q3 FY2026 Earnings Call Summary

Moderna reported strong third-quarter 2026 results, exceeding expectations with 29% revenue growth and a significant turnaround to net income, driven by robust vaccine sales and pipeline advancements. The company also raised its full-year revenue guidance and improved its cash outlook, signaling increasing confidence in its diversified growth strategy beyond COVID-19.

Moderna's management expressed strong confidence in the company's trajectory, significantly raising its full-year 2026 total revenue growth outlook to an impressive 15%-25%, a substantial increase from the previous expectation of up to 10% growth. This revised guidance underscores management's belief in continued commercial momentum and market penetration. Furthermore, the company improved its 2026 GAAP operating expense outlook by approximately $0.2 billion and substantially increased its expected year-end cash and investments to a range of $8.1 billion to $8.3 billion. Looking ahead, CEO Stéphane Bancel highlighted anticipated additional intismeran readouts, pivotal data in propionic acidemia, and further regulatory approvals as key drivers for advancing the pipeline and building a more diversified company.

We delivered 29% revenue growth in the third quarter, alongside the U.S. approval of mFLUSIVA, our fifth approved product globally, and positive Phase 3 results for intismeran in melanoma. Building on this momentum, we increased our full-year revenue growth outlook to 15%-25%, while continuing to reduce costs and strengthen our balance sheet. Looking ahead, we anticipate additional intismeran readouts, pivotal data in propionic acidemia and further regulatory approvals as we advance our pipeline and build a more diversified company." — Stéphane Bancel, Chief Executive Officer